DIO2与MCT10基因多态性与英国生物银行中左甲状腺素治疗患者持续症状的关联
基于英国生物银行的横断面研究纳入18761例左甲状腺素治疗患者和360534名对照,评估DIO2基因rs225014、rs225015、rs12885300及MCT10基因rs17606253与心理幸福感、认知功能和心血管危险因素的关联;除rs225015次要A等位基因与财务不满意显著相关外,这些单核苷酸变异与任何结局均无关联,也不放大左甲状腺素治疗相关症状。
要点
- 左甲状腺素治疗与疲乏频率增加、幸福感因子评分降低、反应时间增加和体重指数增加相关(P < .001)。
- rs225014、rs225015、rs12885300和rs17606253与左甲状腺素治疗患者的心理幸福感、认知功能或心血管危险因素无关联。
- 携带这4个单核苷酸变异的风险等位基因未放大左甲状腺素治疗相关症状。
核心结论
- rs225014、rs225015、rs12885300和rs17606253不能解释左甲状腺素治疗患者心理幸福感、认知功能或心血管危险因素的改变,研究结果不支持这些单核苷酸变异与左甲状腺素治疗之间存在基因-治疗交互作用。
研究设计与样本
- 基于英国生物银行的群体横断面研究,纳入18761例左甲状腺素治疗患者和360534名对照;左甲状腺素治疗定义为甲状腺功能减退症诊断且自我报告使用左甲状腺素而未使用3,5,3'-三碘甲状腺原氨酸。
主要发现
- 与对照相比,左甲状腺素治疗与几乎所有结局不良相关,最值得注意的是疲乏频率增加(P < .001)、幸福感因子评分降低(P < .001)、反应时间增加(P < .001)和体重指数增加(P < .001)。
- 除rs225015次要A等位基因与财务不满意存在显著关联外,rs225014、rs225015、rs12885300或rs17606253与左甲状腺素治疗患者的任何结局均无关联。
- 对于所有结局,携带这4个单核苷酸变异的风险等位基因并未放大左甲状腺素治疗相关症状(与对照相比)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Some evidence suggests gene-treatment interactions might cause persistent symptoms in individuals receiving levothyroxine (LT4) treatment. OBJECTIVE: We investigated, as previously hypothesized, if single-nucleotide variations (SNVs; formerly single-nucleotide polymorphisms) in rs225014 (Thr92Ala), rs225015, or rs12885300 (ORFa-Gly3Asp) in the deiodinase 2 gene (DIO2), or rs17606253 in the monocarboxylate transporter 10 gene (MCT10) were associated with outcomes indicative of local tissue hypothyroidism in LT4-treated patients and controls. METHODS: We included 18 761 LT4-treated patients and 360 534 controls in a population-based cross-sectional study in the UK Biobank. LT4 treatment was defined as a diagnosis of hypothyroidism and self-reported use of LT4 without use of 3,5,3'-triiodothyronine. Outcomes were psychological well-being, cognitive function, and cardiovascular risk factors. Associations were evaluated by linear, logistic, or ordinal logistic multiple regression. Adjustments included sex, age, sex-age interaction, and genetic principal components 1 to 10. RESULTS: Compared to controls, LT4 treatment was adversely associated with almost all outcomes, most noteworthy: Increased frequency of tiredness (P < .001), decreased well-being factor score (P < .001), increased reaction-time (P < .001), and increased body mass index (P < .001). Except for a significant association between the minor rs225015 A allele and financial dissatisfaction, there was no association of rs225014, rs225015, rs12885300, or rs17606253 with any outcomes in LT4-treated patients. For all outcomes, carrying the risk allele at these 4 SNVs did not amplify symptoms associated with LT4 treatment compared to controls. CONCLUSION: rs225014, rs225015, rs12885300, and rs17606253 could not explain changed psychological well-being, cognitive function, or cardiovascular risk factors in LT4-treated patients. Our findings do not support a gene-treatment interaction between these SNVs and LT4 treatment.
引用
- Jensen CZ, Isaksen JL, Ahlberg G, et al. Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank. J Clin Endocrinol Metab. 2024. PMID: 37740545. doi:10.1210/clinem/dgad556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。